NCT04542616View on ClinicalTrials.gov

Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Glaucoma
Interventions
DEVICE

Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation

Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.

Trial Locations (1)

14209

The Ira G. Ross Eye Institute, Buffalo

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT04542616 - Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma | Biotech Hunter | Biotech Hunter